| 000 | 01794 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250513194829.0 | ||
| 264 | 0 | _c19991217 | |
| 008 | 199912s 0 0 eng d | ||
| 022 | _a0315-162X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChoy, E H | |
| 245 | 0 | 0 |
_aThe engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis. _h[electronic resource] |
| 260 |
_bThe Journal of rheumatology _cNov 1999 |
||
| 300 |
_a2310-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntibodies _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _ximmunology |
| 650 | 0 | 4 |
_aAutoantibodies _xanalysis |
| 650 | 0 | 4 |
_aCD4 Antigens _xblood |
| 650 | 0 | 4 |
_aCollagen _xurine |
| 650 | 0 | 4 | _aCollagen Type I |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-6 _xblood |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xphysiology |
| 650 | 0 | 4 | _aLymphocyte Activation |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 3 _xblood |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptides _xurine |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aReceptors, Interleukin-2 _xblood |
| 650 | 0 | 4 |
_aRecombinant Proteins _ximmunology |
| 650 | 0 | 4 |
_aT-Lymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _ximmunology |
| 700 | 1 | _aRankin, E C | |
| 700 | 1 | _aKassimos, D | |
| 700 | 1 | _aVetterlein, O | |
| 700 | 1 | _aGaryfallos, A | |
| 700 | 1 | _aRavirajan, C T | |
| 700 | 1 | _aSopwith, M | |
| 700 | 1 | _aEastell, R | |
| 700 | 1 | _aKingsley, G H | |
| 700 | 1 | _aIsenberg, D A | |
| 700 | 1 | _aPanayi, G S | |
| 773 | 0 |
_tThe Journal of rheumatology _gvol. 26 _gno. 11 _gp. 2310-7 |
|
| 999 |
_c10512458 _d10512458 |
||